secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vistagen Therapeutics, Inc. (VTGN)
CIK:        0001411685
Form:       8-K
Filed at:   2023-10-26T23:59:59+00:00
Accession:  0001437749-23-029096
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Joshua Prince appointed COO of Vistagen Therapeutics
----------------------------------------------------

- Joshua Prince appointed Chief Operating Officer effective Oct 24, 2023; had been SVP Business Operations since Nov 2021.
- Prince brings over 20 years pharma experience including roles at CSL Behring, Teva, and AstraZeneca.
- Holds a BS in Mechanical Engineering from Missouri-Rolla and an MBA from Penn State.
- Company entered into standard Indemnification Agreement with Prince for his service.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1411685/000143774923029096/0001437749-23-029096-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1411685/000143774923029096/vtgn20231026_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-029096

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer